Condition
Postreperfusion Syndrome
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 4 (2)
Trial Status
Unknown2
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04203004Not ApplicableUnknown
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
NCT05754242Phase 2Unknown
Ascorbic Acid to Prevent Postreperfusion Syndrome in Liver Transplantation
NCT01886664Phase 4Completed
Comparison of PRS According to Inhalation Agent During LDLT
NCT01001403Phase 4Completed
Effect of Nafamostat on Postreperfusion Syndrome (PRS)
Showing all 4 trials